OTHER NOVEL AGENTS: RATIONALE AND CURRENT STATUS AS CHEMOPREVENTIVE AGENTS
Several novel targets are currently being evaluated both preclinically and clinically for the prevention of prostate cancer. Four divergent and novel approaches were discussed at the National Cancer Institute-sponsored workshop entitled, “New Clinical Strategies in Prostate Cancer Prevention.”These intervention are further categorized into soy protein-based serine-protease inhibitors that reduce superoxide-induced DNA damage, and molecularly targeted approaches that are directed toward endothelin-1 expression/overexpression , peroxisome
proliferator-activated receptor ligands, and insulinlike growth factors. Understanding
each of these approaches has offered insights into the process of malignant transformation of prostatic epithelium, and further illustrates the difficulties of developing new agents in the treatment and prevention of prostate cancer. Close scrutiny of the clinical data emerging with these approaches, including validation of biologic endpoints, is required before large-scale prevention studies with these novel agents and targets can be considered.
Several novel agents that are currently undergoing clinical evaluation were discussed at the recent National Cancer Institute workshop on “New Clinical Trials: Strategies in Prostate Cancer Chemoprevention.” This overview of the agents highlights both the strengths and weaknesses associated with their application to prostate cancer chemoprevention.
- 1 0 年前最佳解答
其他的新奇 AGENTS： 原理和現在的狀態當做 CHEMOPREVENTIVE AGENTS
一些新奇的目標現在對於前列腺癌症的預防正在潛伏期地而且臨床地被評估。四個分歧的和新奇的方法在被取名為的美國國家癌症研究所贊助的工作室被討論，”前列腺的巨蟹座預防的新的臨床策略。”這些干涉進入大豆之內更進一步被分類減少 superoxide 的以蛋白質為基礎的 serine－蛋白的抑制劑－在參考資料： 網路翻譯~~